←
Thomas Zilli2,918 posts
Thomas Zilli avatar✓

Thomas Zilli ✓

@ZilliThomas

Radiation Oncology, IOSI - Oncology Institute of Southern Switzerland, EOC, Switzerland

◷ Joined September 2018▧ 66 Photos and videos
GFRU avatar
⟳ Thomas Zilli retweeted
GFRU@GFRU_meeting·21h

Focus Atelier de contourage 2027 : la loge prostatique Animé par @jolicom et @ChapetOlivier ➡️Approfondir les méthodes, confronter les pratiques, bénéficier de l’expertise de spécialistes 🇫🇷🇨🇦🇧🇪🇨🇭 Rdv les 1 et 2 avril 2027 à #Lyon 💻 : site.imagina.com/gfru

ESTRO avatar
⟳ Thomas Zilli retweeted
ESTRO@ESTRO_RT·Nov 9

#EMUC26 wrapped up yesterday! In the closing session, Prof Thomas Zilli shared key takeaways on #RadOnc as a core pillar of #GUcancer care. 🎥 Watch below & stay tuned as we share more interviews this week! 👇@ZilliThomas

1:57
Enrique Grande avatar
⟳ Thomas Zilli retweeted
Enrique Grande@drenriquegrande·Nov 5

Renal GPA update in RCC with brain metastases (n=1,049; 21 institutions): median OS 20.0 months in patients treated 2016–2022, vs 9.6 and 12.0 months in legacy cohorts. The updated Renal GPA stratifies median survival from 4.8 to 51.2 months. Retrospective data. #KidneyCancer #RCC #GUOncology

Post attachmentPost attachmentPost attachment
Enrique Grande avatar
⟳ Thomas Zilli retweeted
Enrique Grande@drenriquegrande·Oct 25

PE-PE population: a new concept for oligonetastatic definition in RCC. Thanks @DrIacovelli for bringing up!!! Something that we were assuming and using in the clinic is now confirmed. Pembrolizumab should be offer as “adjuvant” treatment for oligometastatic PE-PE+ ccRCC patients. My question is; : what is the value/contribution of giving 1 cicle before SBRT/surgery? @myESMO @OncoAlert

Post attachmentPost attachment
Alan Tan avatar
⟳ Thomas Zilli retweeted
Alan Tan@alantanmd·Oct 24

One year of APA+ADT comes with toxicity, and outcomes after control-arm salvage aren't shown. His view: follow-up too short; would not yet support perioperative APA+ADT with RP in high-risk disease, needing mature survival and post-salvage data first.

Post attachmentPost attachmentPost attachmentPost attachment
Alfredo Addeo MD avatar
⟳ Thomas Zilli retweeted
Alfredo Addeo MD@Alfdoc2·Oct 25

🚨 #ESMO26 | SARON: Better PFS, but NO overall survival benefit! @fifimcdrmh presents the randomized phase II SAFRON trial in synchronous oligometastatic, driver-negative NSCLC. 📊 Median OS: 🔹 SACT alone: 28.0 months 🔹 SACT + consolidative RT: 31.0 months 🔹 HR 0.99 (95% CI 0.63–1.55), p=0.95 ✅ Better disease control and longer PFS with RT. ❌ But NO OS benefit demonstrated! An important reminder: improving PFS does not necessarily translate into longer survival. Thought-provoking data challenging the routine use of consolidative RT in this setting! #ESMOAmbassadors #ESMO26 #LungCancer #NSCLC

Post attachmentPost attachmentPost attachment
Zach Klaassen avatar
⟳ Thomas Zilli retweeted
Zach Klaassen@zklaassen_md·Oct 24

#ESMO26 DASL-HiCaP Presidential Discussant -- @Silke_Gillessen Differences in BL risk and pt selection may explain variation in treatment effects for STAMPEDE M0, ENZARAD, DASL-HiCaP Among N1 pts only, ARPI MFS benefit: ◾️STAMPEDE M0: HR 0.49, 95%CI 0.38-0.64 ◾️ENZARAD: HR 0.43, 95%CI 0.20-0.92 ◾️DASL-HiCaP: HR 0.39, 95%CI 0.19-0.81

Post attachmentPost attachmentPost attachment
Toni Choueiri, MD avatar
⟳ Thomas Zilli retweeted
Toni Choueiri, MD@DrChoueiri·Oct 23

Encouraging OS results in neuroendocrine prostate cancer at #ESMO26! #KEYNOTE-365 evaluated pembrolizumab + carboplatin/etoposide vs chemotherapy alone. • mOS: 10.2 vs 7.1 months (HR 0.33) • rPFS: 5.1 vs 4.0 months (HR 0.66) • PD-L1 CPS ≥1: mOS 11.0 vs 4.8 months (HR 0.16) No new safety signals observed. @myESMO @oncoalert

Post attachmentPost attachmentPost attachmentPost attachment